Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.

Magee MS, Abraham TS, Baybutt TR, Flickinger JC Jr, Ridge NA, Marszalowicz GP, Prajapati P, Hersperger AR, Waldman SA, Snook AE.

Cancer Immunol Res. 2018 May;6(5):509-516. doi: 10.1158/2326-6066.CIR-16-0362. Epub 2018 Apr 3.


GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.

Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE.

Oncoimmunology. 2016 Sep 2;5(10):e1227897. eCollection 2016.


GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.

Marszalowicz GP, Snook AE, Magee MS, Merlino D, Berman-Booty LD, Waldman SA.

Oncotarget. 2014 Oct 15;5(19):9460-71.


Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.

Gibbons AV, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S, Snook AE, Schulz S, Waldman SA.

Cancer Res. 2013 Nov 15;73(22):6654-66. doi: 10.1158/0008-5472.CAN-13-0887. Epub 2013 Oct 1.


Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Magee MS, Snook AE, Marszalowicz GP, Waldman SA.

Biomark Med. 2013 Feb;7(1):23-35. doi: 10.2217/bmm.12.110. Review.


Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.

Snook AE, Magee MS, Marszalowicz GP, Schulz S, Waldman SA.

Cancer Immunol Immunother. 2012 May;61(5):713-23. doi: 10.1007/s00262-011-1133-0. Epub 2011 Nov 6.

Supplemental Content

Loading ...
Support Center